PRF Technologies Ltd. Stock Price, News & Analysis
Company Description
PainReform Ltd. (Nasdaq: PRFX) is a specialty pharmaceutical and technology company whose activities span post-surgical pain management and AI-driven energy analytics. According to its public disclosures, the company focuses on the reformulation of established therapeutics using proprietary extended-release drug-delivery systems, and on the development of AI-based software that helps monitor, forecast, and optimize energy use in solar-integrated environments through its DeepSolar platform.
In its pharmaceutical division, PainReform develops programs that leverage a proprietary extended-release drug-delivery system intended to provide prolonged post-surgical pain relief while minimizing the need for repeated dosing and reducing reliance on opioids. The company has described itself as a clinical-stage specialty pharmaceutical company and has highlighted its focus on non-opiate approaches to pain management in surgical settings.
One of PainReform’s key pharmaceutical assets is PRF-110, described as an oil-based, viscous, clear solution based on the local anesthetic ropivacaine and targeting the post-operative pain relief market. PRF-110 is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia. The company has reported that PRF-110 demonstrated meaningful efficacy in the early part of the postoperative period in a bunionectomy trial and that it is conducting additional research and development to refine the program.
PainReform has also expanded into ophthalmology through a majority investment in LayerBio, Inc., a biotechnology company advancing sustained-release drug delivery technologies in ophthalmology. LayerBio’s lead product candidate, OcuRing™-K, is a patent-protected, sustained-release intraocular ring designed to deliver ketorolac, a non-opiate, non-steroidal anti-inflammatory and analgesic drug, following cataract surgery. OcuRing-K is placed intraoperatively during cataract procedures and is described as a “dropless” therapy intended to replace traditional post-surgical eye-drop regimens that often involve multiple daily corticosteroid and NSAID drops.
The OcuRing-K platform is designed to provide controlled, localized, and extended release of therapy directly at the surgical site, with the goal of eliminating patient-administered drops, improving compliance, and reducing systemic exposure. PainReform has reported that LayerBio’s technology allows extended drug release from a single application, offers site-specific delivery to maximize local effect, and uses a biodegradable design that eliminates the need for device removal. Company communications also state that the platform can support delivery of a range of ocular therapeutics, including NSAIDs, antibiotics, steroids, and anti-VEGF agents.
PainReform and LayerBio have disclosed a development path for OcuRing-K that includes preclinical studies and clinical trials. Preclinical rabbit studies and a Phase I clinical study in cataract surgery patients have been reported to show a favorable safety profile for OcuRing™-K’s drop-less, sustained-release ocular drug-delivery platform, with no treatment-emergent adverse events related to the study drug and no serious adverse events identified in the Phase I study. The investigational product and intraocular lens devices were reported to remain properly positioned in all treated eyes. Based on these findings, the company has indicated that it is advancing toward later-stage development and IND-enabling activities.
Beyond OcuRing-K, PainReform has described LayerBio’s sustained-release, polymer matrix platform as capable of incorporating a variety of drug entities, including corticosteroids and NSAIDs, reinforcing the potential for multi-drug loading and broader ophthalmic applications. Company statements reference the long-term goal of reducing or eliminating reliance on medicated eye drops in cataract surgery and potentially in other ophthalmic indications.
On the energy side of its business, PainReform operates the DeepSolar platform, which it characterizes as a developer of advanced digital-asset-management technologies for utility-scale solar plants. DeepSolar’s AI-driven algorithms are described as transforming complex operational data into insights that detect issues, forecast production, and support decision-making to maximize asset performance and profitability. The company reports that DeepSolar delivers advanced software solutions that enable both consumers and enterprises to monitor, forecast, and optimize energy consumption, particularly in solar-integrated environments.
DeepSolar’s activities include the development of DeepSolar Predict, an AI-based forecasting module built specifically for photovoltaic systems and advanced within the NVIDIA Connect program. According to company press releases, DeepSolar Predict is designed to enhance weather-driven energy production forecasts and help solar-asset managers reduce imbalance risks and improve profitability by combining advanced weather modeling with AI-optimized computation. PainReform has also described DeepSolar’s participation in the NVIDIA Connect program, which provides access to AI frameworks, development tools, and engineering support.
In addition, DeepSolar has introduced Smart TDD, an advanced solar technical due diligence service that aims to provide faster and more comprehensive assessments of solar asset performance and risk. Company materials state that Smart TDD is engineered to audit complete data coverage across components and operational history, apply AI-driven analytics with physics-based modeling and expert review, and deliver prioritized findings with rapid turnaround. DeepSolar has also advanced an automated reporting engine intended to consolidate and interpret data from multiple sources and generate tailored performance reports for stakeholders in minutes.
PainReform has reported that DeepSolar’s software platform has demonstrated the ability to enhance energy production and reduce operations and maintenance costs, and that it has progressed from pilot projects into initial commercial agreements, such as a 92MW pilot project with Econergy Renewable Energy in Romania that advanced into a commercial customer agreement. The company positions this dual focus on specialty pharmaceuticals and renewable-energy analytics as a strategic commitment to applying precision technology across healthcare and sustainable energy sectors.
Business Segments
Based on its public communications, PainReform’s activities can be viewed in two main areas:
- Specialty pharmaceutical programs focused on reformulating established therapeutics and developing sustained-release drug-delivery technologies for post-surgical pain and ophthalmic indications, including PRF-110 and the OcuRing-K platform via its majority-owned subsidiary LayerBio.
- AI-driven energy analytics through the DeepSolar platform, which develops digital-asset-management technologies, forecasting tools such as DeepSolar Predict, and services such as Smart TDD and automated reporting for solar assets and energy optimization.
Regulatory and Listing Context
PainReform Ltd. files reports with the U.S. Securities and Exchange Commission as a foreign private issuer, including multiple Form 6-K current reports that furnish press releases, financial statements, and transaction disclosures. The company’s ordinary shares trade on Nasdaq under the symbol PRFX. Its SEC filings reference registration statements on Form F-3 and Form S-8, reflecting its status as a listed issuer accessing U.S. capital markets.